サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1138360

サラセミア治療の世界市場-2022-2029

Global Thalassemia Treatment Market - 2022-2029
出版日: | 発行: DataM Intelligence | ページ情報: 英文 200 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
サラセミア治療の世界市場-2022-2029
出版日: 2022年10月18日
発行: DataM Intelligence
ページ情報: 英文 200 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場力学

サラセミア治療市場の成長は、サラセミアの有病率の増加、世界の認知度の上昇、研究開発への投資の増加など、いくつかの要因に牽引されています。

サラセミアに関する認知度の向上は、市場成長の原動力になると予想されます。

サラセミアに関する認知度の向上は、この病気の予防に非常に重要です。多くの組織が啓発キャンペーンを開始し、この目的のために活動しています。各国政府も、これらのプログラムに投資することで、この活動を支援しています。例えば、5月8日の国際サラセミアデーは、意思決定や政策決定に関わる人々、医療従事者、患者やその家族、そして地域社会全体にサラセミアに対する認識を高めるために祝われています。特にアジア太平洋地域や地中海沿岸地域など、より流行している地域では、国民の大多数がこの病気について知らないでいます。米国疾病対策予防センター（CDC）は、血液疾患患者の血液の安全性を監視する1つのプロジェクトに資金を提供しています。このプロジェクトは、"ヘモグロビン異常症に対する治療用輸血に関連する合併症の特徴"と呼ばれています。ジョージア州立大学、フロリダ大学、カリフォルニア大学サンフランシスコ校ベニオフ子供病院オークランド校は、ヘモグロビン障害（鎌状赤血球症、サラセミア）の人々の輸血関連の合併症を調べ、これらの合併症を減らすためのアプローチを開発するための資金を獲得しています。そのほか、CDCは公衆衛生検査所協会に資金を提供し、検査所に対するニーズ調査などのスクリーニング（病気を自覚する前に調べる検査）活動や、患者、介護者、医療従事者に対するヘモグロビン症スクリーニングプログラムに関する教育などの公衆衛生技術支援を行っています。

治療費の高さが、世界のサラセミア治療市場の成長の妨げになると予想されます。

治療費の高さが、世界のサラセミア治療市場の成長を妨げると予想されます。

産業分析。

世界のサラセミア治療市場レポートでは、Porter`s Five Force、イノベーション、新製品発表、価格分析、パイプライン分析など、さまざまな業界要因に基づく市場の詳細な分析を提供します。

COVID-19の影響分析

COVID-19は世界のサラセミア治療市場に大きな影響を及ぼしています。COVID-19封じ込めプロトコル以来、多くの市場プレイヤーのサプライチェーンが混乱し、原材料の不足を引き起こし、需給連鎖を乱したのです。さらに、社会化規制のため、定期的な健康診断が難しく、ほとんどのサラセミア患者が発見されず、パンデミック中の世界のサラセミア治療市場の成長にマイナスの影響を及ぼしました。

世界のサラセミア治療市場- セグメント分析

予測期間（2022-2029年）を通して、α-サラセミアはサラセミア治療市場を独占すると予想されます。

アルファ型サラセミアは、世界的に有病率が高いため、予測期間（2022-2029年）において最大の市場シェアを占めると予想されます。全米希少疾患機関によると、アルファサラセミアは出生1,000人あたり4～20人に発症します。アルファサラセミアは、世界中のほとんどの人口に見られますが、中東、東南アジア、地中海沿岸の一部の国で最も多く見られます。欧州や北米の医師も、移住の増加に伴い、αサラセミアの患者さんに遭遇することが多くなっています。アルファサラセミアは、ヘモグロビンの構成要素を作るのに必要な遺伝子の変異によって引き起こされる遺伝性疾患です。これらの変異により、ヘモグロビンの生成が妨げられるか減少するため、成熟した赤血球が不足し、貧血を引き起こすことがあります。アルファサラセミアの原因となる突然変異は、アジア、インド、中東、地中海沿岸で多く見られ、人口の最大20%に見られます。しかし、現代人の移住の増加により、他の地域でも症例が多く見られるようになっています。南地中海沿岸諸国は、α-サラセミア患者の増加を認識し、増大する需要に適切に対応するために資源を増強しており、その結果、α-サラセミア治療薬の市場が世界的に拡大しています。

世界のサラセミア治療市場レポートでは、約40以上の市場データ表、45以上の図表、200ページ（概算）の範囲でのアクセスを提供することになります。

目次

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場の力学

  • 市場影響要因
    • 促進要因
      • 認知度の向上
      • 研究開発の進展
    • 抑制要因
      • 高い開発コスト
      • 高い治療費
    • ビジネスチャンス
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 規制分析

第6章 COVID-19の分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、または将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的取り組み
  • まとめ

第7章 疾患タイプ別

  • アルファサラセミア
  • ベータサラセミア

第8章 治療タイプ別

  • 輸血
  • 鉄キレート療法
  • 骨髄移植
  • 遺伝子治療
  • 外科手術

第9章 投与経路別

  • 経口
  • 注射剤

第10章 エンドユーザー別

  • 病院・診療所
  • その他

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第12章 競合情勢

  • 主な展開と戦略
  • 企業シェア分析
  • 製品ベンチマーク

第13章 企業プロファイル

  • Bristol-Myers Squibb Company
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Vifor Pharma
  • Kiadis Pharma
  • Gamida Cell
  • ApoPharma
  • bluebird bio, Inc.
  • Novartis AG
  • Celgene Corporation,
  • La Jolla Pharmaceutical
  • Sangamo Biosciences
  • Acceleron Pharma.

第14章 DataM

目次
Product Code: DMPH2148

Market Overview

Thalassemia Treatment Market is expected to grow at a CAGR of 10.5% during the forecasting period (2022-2029).

Thalassemia is an inherited blood disorder that reduces the production of functional hemoglobin, the protein in red blood cells that carries oxygen. This causes a shortage of red blood cells and low oxygen levels in the bloodstream, leading to various health problems. Signs and symptoms vary but may include mild to severe anemia, paleness, fatigue, yellow discoloration of the skin, and bone problems. When there are not enough healthy red blood cells, there is also not enough oxygen delivered to all the other cells of the body, which may cause a person to feel tired, weak or short of breath. This is a condition called anemia. People with thalassemia may have mild or severe anemia. Severe anemia can damage organs and lead to death.

Market Dynamics

The thalassemia treatment market growth is driven by several factors, such as an increase in the prevalence of thalassemia, a rise in global awareness and, increasing investment in research and development.

The rising awareness about thalassemia is expected to drive market growth.

An increase in awareness about thalassemia is very important for the prevention of the disease. Many organizations are working towards this cause by initiating awareness campaigns. Governments of countries are also supporting the cause by investing in these programs. For instance, International Thalassaemia Day is celebrated on May 8 to raise awareness amongst people concerned with decision and policymaking, health care professionals, patients and their families and the community at large about thalassemia. The majority of the population is unaware of the disease, especially in more prevalent areas, such as the Asia Pacific and the Mediterranean. The Center for Disease Control and Prevention (CDC) funds one project that monitors blood safety in people with blood disorders. This project is called "Characterizing the Complications Associated with Therapeutic Blood Transfusions for Hemoglobinopathies." Georgia State University, the University of Florida, and the University of California at San Francisco Benioff Children's Hospital Oakland have been awarded funding to look at transfusion-related complications in people with hemoglobin disorders (sickle cell disease and thalassemia) and develop approaches for reducing these complications. Besides, CDC funds the Association of Public Health Laboratories to provide public health technical assistance with screening (a test to look for a disease before it is noticeable) activities, including needs assessments for laboratories, as well as education for patients, caregivers, and healthcare workers on hemoglobinopathy screening programs.

The high cost of treatment is expected to hinder global thalassemia treatment market growth.

The high cost of treatment is expected to hamper the global thalassemia treatment market growth.

Industry analysis.

The global thalassemia treatment market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, innovations, new product launches, pricing analysis, and pipeline analysis.

COVID-19 Impact Analysis

COVID-19 has significantly impacted the global Thalassemia Treatment market. Since COVID-19 containment protocols, the supply chain of many market players was disrupted and caused a lack of raw materials to disturb the supply and demand chain. Furthermore, because of the socializing restrictions, regular healthcare checkups were difficult, leaving most patients with thalassemia undetected, negatively impacting the global Thalassemia Treatment market growth during the pandemic.

Global Thalassemia Treatment Market - Segment Analysis

The alpha-thalassemia is expected to dominate the thalassemia treatment market throughout the forecast period (2022-2029)

Alpha thalassemia is expected to hold the largest market share over the period forecast (2022-2029) owning to a higher prevalence of the disease globally. According to National Organization for Rare Disorders, alpha thalassemia occurs in 4-20 individuals per every 1,000 births. Alpha thalassemia is found in most populations worldwide but is most common in the Middle East, Southeast Asia, and certain Mediterranean countries. Doctors in Europe and North America are also increasingly encountering patients with alpha-thalassemia due to increased migration. Alpha-thalassemia is an inherited disease caused by mutations in a gene required for making a component of hemoglobin. Those mutations either prevent or reduce the production of hemoglobin, which can cause a shortage of mature red blood cells and lead to anemia. The mutations that cause alpha-thalassemia are more common in Asia, India, the Middle East and the Mediterranean where they are found in up to 20% of the population. But the increase in modern migration means that cases are now cropping up more often in other regions. Southern Mediterranean countries recognize the rise in patients with alpha-thalassemia and have increased resources to meet the growing demand appropriately, hence increasing the market for alpha-thalassemia treatment globally.

Geographical Analysis

The North American region holds the largest market share of the global thalassemia treatment market.

North America is dominating the thalassemia treatment market in 2018 and is estimated to hold the largest market size over the forecast period (2022-2029), owing to an increase in thalassemia incidences, highly aware population, advanced healthcare infrastructure and favorable government initiatives. The cases of thalassemia disorder are increasing in the region due to migration. Thalassemia, once a rarity in the US, is increasingly encountered in clinical practice due to shifts in immigration. Thalassemia is becoming more prevalent in the US due to the immigration of people from affected regions; according to Cooley's Anemia Foundation, 12% of patients with B-thalassemia in their US patient database were adopted from other countries. Furthermore, many organizations and societies are working in this region to spread awareness about thalassemia and ensure its dominance over the global market.

Competitive Landscape

Some of the major key players in the market are Vifor Pharma, Kiadis Pharma, Gamida Cell, ApoPharma, bluebird bio, Inc., Novartis AG, Bristol-Myers Squibb Company, Celgene Corporation, La Jolla Pharmaceutical, Sangamo Biosciences, and Acceleron Pharma. In the thalassemia treatment market, bluebird bio-Inc. will dominate the market, owning to portfolio expansion, mergers, collaborations, and acquisitions. The key players are adopting various growth strategies such as mergers & acquisitions, partnerships, and collaborations and increasing research and development and high investment, which are contributing to the growth of the thalassemia treatment market globally. For instance, on April 16, 2021, Sanofi acquired Kiadis. Also, on December 22, 2021, Novartis acquired Gyroscope Therapeutics.

Bristol-Myers Squibb Company

Overview:

The Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York City. BMS is a leading pharmaceutical company and has consistently ranked among the largest U.S. corporations. For fiscal 2021, it had total revenue of $46.4 billion.

Product Portfolio:

The product portfolio of Bristol-Myers Squibb Company for thalassemia treatment contains REBLOZYL.

The global thalassemia treatment market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Awareness
      • 4.1.1.2. Research and Development
    • 4.1.2. Restraints
      • 4.1.2.1. The High Development Cost
      • 4.1.2.2. High Treatment Cost
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Disease Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type Segment
    • 7.1.2. Market Attractiveness Index, By Disease Type Segment
  • 7.2. Alpha Thalassemia
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Beta Thalassemia

8. By Treatment Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type Segment
    • 8.1.2. Market Attractiveness Index, By Treatment Type Segment
  • 8.2. Blood Transfusion
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Iron Chelation Therapy
  • 8.4. Bone Marrow Transplant
  • 8.5. Gene Therapy
  • 8.6. Surgery

9. By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of administration Segment
    • 9.1.2. Market Attractiveness Index, By Route of administration Segment
  • 9.2. Oral
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Injectable

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User Segment
  • 10.2. Hospitals and Clinics
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Other

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. The U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. The U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking

13. Company Profiles

  • 13.1. Bristol-Myers Squibb Company
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Vifor Pharma
  • 13.3. Kiadis Pharma
  • 13.4. Gamida Cell
  • 13.5. ApoPharma
  • 13.6. bluebird bio, Inc.
  • 13.7. Novartis AG
  • 13.8. Celgene Corporation,
  • 13.9. La Jolla Pharmaceutical
  • 13.10. Sangamo Biosciences
  • 13.11. Acceleron Pharma.

LIST NOT EXHAUSTIVE

14. DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us